Over the last 10 years the face of clinical R&D and pharmacovigilance (PV) outsourcing has dramatically changed. What was a common industry scenario by 2010 — a full-scale operational pharma company utilizing both international and U.S.-based CROs to execute clinical investigator site monitoring and data management — has evolved into a new common scenario in 2019.
By Mathini Ilancheran, principal analyst, R&D, Beroe Inc.
Pharmaceutical companies have three targeted users: physicians, pharmacists, and patients. Various digital platforms are used to create a good customer experience for educating these end users. The core focus is on patients driving patient care, education, and adherence.
With most sponsors utilizing an outsourcing model of some kind, the biggest opportunity might still lie ahead. As the industry adapts to be more budget-minded and efficient, the quest for innovation remains. So, what does meaningful innovation look like for the clinical trial industry?
Less than 10 percent of oncology patients actually participate in clinical trials. How can a trial be easy or effective if patient participation is low? Get the tips you need to run better early-phase oncology trials now.
In this webinar, medical and operations experts from Medpace facilitate a Q&A session with Dr. Stephen A. Harrison, an experienced key opinion leader (KOL) in NASH. The presenters participate in an in-depth discussion on selected topics associated with NASH development as well as strategies and opportunities for researchers.